Ert Pompe denied for missing prior authorization by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas Requires Prior Authorization for ERT in Pompe Disease

Enzyme replacement therapy (ERT) for Pompe disease is a high-cost specialty medication for a rare, life-threatening condition. AmeriHealth Caritas, like most Medicaid managed-care plans, requires prior authorization (PA) to confirm the diagnosis is established, the prescriber has the appropriate specialty, and the requested treatment aligns with its published coverage criteria. A PA denial — or a lapse that results in a claim denial — is almost always appealable on the merits.

## Why This Denial Is Appealable

Pompe disease is a recognized FDA-approved indication for ERT. If the PA was denied because documentation was incomplete at submission, the appeal is an opportunity to supply the missing clinical evidence. If the PA was denied on a clinical basis, you can challenge the insurer's criteria against the FDA-approved prescribing label and specialist-society guidance.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on your denial letter or EOB. AmeriHealth Caritas must adjudicate non-urgent appeals within 30 days; urgent/expedited appeals within 72 hours. Because Pompe disease is progressive, document clinical urgency explicitly.
• External review (ACA §2719): Available after exhausting internal appeals (or if the plan waives that requirement). An independent review organization (IRO) — not affiliated with the insurer — evaluates whether the denial is consistent with generally accepted medical standards. Expedited external review is available when a standard timeline would seriously jeopardize health.
• ERISA §503 (employer-sponsored plans): You are entitled to the full claims file, including all clinical criteria applied and the credentials of any reviewing clinician.

The external-review request window is typically four months from final internal denial.

## Documentation to Gather

• Confirmed Pompe disease diagnosis: Genetic analysis (GAA mutation) and/or enzyme activity assay from an appropriate laboratory, interpreted by a metabolic disease or neuromuscular specialist.
• Clinical severity documentation: Recent functional assessments, respiratory function testing, motor function evaluations, and any records of disease progression — all dated to show the current clinical picture.
• Prescriber qualifications: Documentation that the ordering physician meets any specialty requirement in the PA criteria (e.g., metabolic disease specialist, neurologist, or pulmonologist depending on presentation).
• Medical necessity letter: A detailed narrative from the treating specialist explaining the diagnosis, disease course, and why ERT is medically necessary — citing the FDA-approved label and applicable specialist-society guidelines by organization name.
• Prior treatment history: Dates and outcomes of any interventions already attempted.

## Criteria-Mapping Structure

Obtain the AmeriHealth Caritas prior authorization criteria for ERT in Pompe disease from their published medical policy. Map each criterion to a specific document:

| PA Criterion | Supporting Evidence | |---|---| | Confirmed Pompe disease (genetic or enzymatic) | [Lab report with date and interpreting clinician] | | Specialist prescriber | [Physician CV or specialty credential] | | Clinical indication consistent with FDA label | [Prescribing label excerpt + treating physician letter] | | Any baseline functional assessment required | [Documented test results from chart] |

Submitting a clean, criterion-by-criterion response — rather than a bulk records dump — significantly increases first-level overturn rates for PA denials.